ANIXA BIOSCIENCES, INC. (ANIX) Gross Margin
- Gross margin · 12 months: Value (m); Formula and calculation Gross profit / revenue. Period ending 2024-10-31..
Gross margin
Overview →Financial period ending 2024-10-31; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | (m) | Gross profit / revenue. Period ending 2024-10-31. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | (m) | |
| Revenue | 210.00K USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2024-10-31 | (m) | $210.00K | (m) | (m) |
| 2024-04-30 | (m) | $210.00K | (m) | (m) |
| 2023-10-31 | (m) | $210.00K | (m) | (m) |
| 2023-07-31 | (m) | (m) | (m) | (m) |
| 2023-04-30 | (m) | (m) | (m) | (m) |
| 2022-04-30 | (m) | $512.50K | (m) | (m) |
| 2022-01-31 | (m) | $512.50K | (m) | (m) |
| 2021-10-31 | (m) | $512.50K | (m) | (m) |
| 2021-07-31 | (m) | (m) | (m) | (m) |
| 2021-04-30 | (m) | (m) | (m) | (m) |
| 2021-01-31 | (m) | (m) | (m) | (m) |
| 2019-10-31 | (m) | $250.00K | (m) | (m) |
| 2019-07-31 | (m) | $250.00K | (m) | (m) |
| 2019-04-30 | (m) | $612.50K | (m) | (m) |
| 2018-10-31 | (m) | $1.11M | (m) | (m) |
| 2018-07-31 | (m) | $1.11M | (m) | (m) |
| 2018-04-30 | (m) | (m) | (m) | (m) |
| 2017-10-31 | (m) | $362.50K | (m) | (m) |
| 2017-07-31 | (m) | $562.50K | (m) | (m) |
| 2016-10-31 | (m) | $300.00K | (m) | (m) |
| 2016-07-31 | (m) | $100.00K | (m) | (m) |
| 2015-10-31 | (m) | $9.26M | (m) | (m) |
| 2015-07-31 | (m) | $10.63M | (m) | (m) |
| 2015-04-30 | (m) | $11.72M | (m) | (m) |
| 2015-01-31 | (m) | (m) | (m) | (m) |
| 2014-10-31 | (m) | $3.67M | (m) | (m) |
| 2014-07-31 | (m) | $2.68M | (m) | (m) |
| 2014-04-30 | (m) | $1.49M | (m) | (m) |
| 2013-10-31 | (m) | $388.85K | (m) | (m) |
| 2013-07-31 | (m) | $2.48K | (m) | (m) |
| 2013-04-30 | (m) | $251.95K | (m) | (m) |
| 2013-01-31 | (m) | $500.02K | (m) | (m) |
| 2012-10-31 | (m) | $947.09K | (m) | (m) |
| 2012-07-31 | (m) | $1.40M | (m) | (m) |
| 2012-04-30 | (m) | $1.60M | (m) | (m) |
| 2012-01-31 | (m) | $1.44M | (m) | (m) |
| 2011-10-31 | (m) | $1.00M | (m) | (m) |
| 2011-07-31 | (m) | (m) | (m) | (m) |
| 2011-04-30 | (m) | (m) | (m) | (m) |
| 2011-01-31 | (m) | (m) | (m) | (m) |
| 2010-10-31 | (m) | $730.67K | (m) | (m) |
| 2010-07-31 | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 |